April 29, 2010 -- The FDA today approved Provenge, Dendreon Corp.'s
individualized "vaccine" for the treatment of advanced prostate cancer.
The action comes more than three years after an
FDA advisory panel recommended approval, declaring the immune therapy safe
and effective. But FDA concerns over efficacy led the FDA to delay a decision
until more data became available.
Provenge doesn't cure prostatecancer or prevent it from
getting worse over time. But it does extend survival -- by months for most
patients, by years for some.
Provenge isn't your everyday vaccine. It's an immune therapy created by
harvesting immune cells from a patient, genetically engineering them to fight
prostate cancer, and then infusing them back into the patient.
It's approved only for treatment of asymptomatic or minimally symptomatic
patients with prostate cancer that has spread outside the prostate and no
longer responds to hormone therapy.
In clinical trials, Provenge extended survival by a median 4.1 months --
about half of patients were below that amount and half were above. But some of
the patients remain alive years after the treatment. In the most recent trial,
32% of Provenge-treated patients remained alive three years after treatment.
Only 23% of placebo-treated patients survived that long.
The approval makes Provenge the first cancer treatment vaccine. It will
"re-energize" work in a field that is littered with disappointing failures,
says Robert Dreicer, MD, chairman of Cleveland Clinic's department of solid
tumor oncology. Dreicer helped run a Provenge clinical trial but has no
financial interest in the product.
"If you asked me two years ago if I thought we were on the cusp of a
cancer-treatment vaccine, I would have said no -- and I would have been wrong,"
Dreicer tells WebMD. "Now we are about to see a series of therapeutic vaccines
that will not be curative, but which will allow us to manage many advanced
cancers in a chronic disease paradigm."
The treatment won't be inexpensive. Industry analysts' estimate of
Provenge's cost range from $40,000 to $100,000, with most analysts betting on
the high end of the range. And the treatment presents a logistical challenge,
as cells taken from patients must be transported to Dendreon facilities,
treated with Provenge and tested for purity and potency, and then returned to a
doctor for infusion.
Ongoing clinical trials are looking at whether Provenge might have more
dramatic effects if given earlier in the course of prostate cancer. One of
these studies is giving Provenge to men intending to undergo prostatectomy for
prostate cancer that is still confined to the prostate gland. Investigators
will examine the removed prostate tissue for signs that Provenge is reducing